Treatment strategy of rectal gastrointestinal stromal tumor (GIST)
- 10 February 2014
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (7), 708-713
- https://doi.org/10.1002/jso.23562
Abstract
Background Rectal gastrointestinal stromal tumor (GIST) is a rare entity. A retrospective analysis of outcomes from a single institution to identify treatment strategies associated with improved outcomes. Methods Records of patients with GIST of the rectum were retrospectively reviewed. Patient and tumor characteristics, treatment details, and outcome were evaluated. Results Compared with the trans-abdominal approach group, the local excision group patients had smaller size and lower location tumors (P < 0.05). Positive resection margin was an important hazard factor for DFS (OR, 7.63; P = 0.015). Among the patients with the tumor size >5 cm, those with preoperative Imatinib therapy had higher rate of a negative resection margin than those without (100% vs. 20%, P = 0.048). Among the patients with intermediate and high-risk tumors, those who received peri-operative Imatinib therapy had longer DFS compared with those without (61.3 ± 6.1 months vs. 20.2 ± 4.4 months, P = 0.030). Conclusions The location of rectal GIST impacts the choice of resection type. Most patients with tumors within 5 cm of the anal verge can be treated with local excision. Positive resection margin is the independent hazard factor for poorer survival. Peri-operative Imatinib therapy is associated with a prolonged DFS in patients with intermediate and high-risk tumors. J. Surg. Oncol 2014; 109:708–713.Keywords
This publication has 16 references indexed in Scilit:
- Surgical management of rectal gastrointestinal stromal tumorsJournal of Surgical Oncology, 2012
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Surgical management of gastrointestinal stromal tumoursBritish Journal of Surgery, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Trans‐sacral (Kraske) approach for gastrointestinal stromal tumour of the lower rectum: old procedure for a new diseaseColorectal Disease, 2008
- Transsacral Approach to Resect a Gastrointestinal Stromal Tumor in the Rectum: Report of Two CasesSurgery Today, 2007
- Clinical, Pathologic, and Immunohistochemical Characteristics of Gastrointestinal Stromal Tumors of the Colon and Rectum: Implications for Surgical Management and Adjuvant TherapiesDiseases of the Colon & Rectum, 2006
- Recent Advances in Cell Biology, Diagnosis and Therapy of Gastrointestinal Stroma Tumor (GIST)Cancer Biology & Therapy, 2004
- Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Rectum and AnusThe American Journal of Surgical Pathology, 2001
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998